PERC, TOPCon or HJT? The emerging technology trends shaping solar cell and module manufacturing in the United States.

In this week's PV Chart of the Week, we look at disparity between announced and operational cell and module manufacturing ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Germany-based Singulus Solar, a joint venture of Singulus Technologies, a German PV equipment manufacturer, and Yingkou Jinchen Machinery, a Chinese module manufacturing equipment supplier, announced ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

The company, a partner of Thornova Solar, says it expects to begin mass production by March 2027, employing as many as 300 ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...

The clinical pipeline for cell and gene therapies is expanding rapidly, but a significant gap remains between preclinical success and regulatory approval. Very few of these advanced therapies reach ...